Timing and intensity of proton pump inhibitor exposure hampers overall survival in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors: a retrospective cohort study.
코호트
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
391 patients included (median age 64.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[DISCUSSION] PPI use around ICI initiation as well as PPI treatment intensity over a wider period was associated with reduced OS. Efforts should be made to streamline PPI use.
[INTRODUCTION] Proton pump inhibitor (PPI) use has been associated with reduced immune checkpoint inhibitor (ICI) efficacy in metastatic non-small cell lung cancer (mNSCLC) with evidence limited to th
- p-value p = 0.045
- p-value p = 0.037
- 95% CI 1.007-1.873
- 연구 설계 cohort study
APA
Japelj N, Horvat N, et al. (2026). Timing and intensity of proton pump inhibitor exposure hampers overall survival in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors: a retrospective cohort study.. Frontiers in immunology, 17, 1682723. https://doi.org/10.3389/fimmu.2026.1682723
MLA
Japelj N, et al.. "Timing and intensity of proton pump inhibitor exposure hampers overall survival in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors: a retrospective cohort study.." Frontiers in immunology, vol. 17, 2026, pp. 1682723.
PMID
41685328 ↗
Abstract 한글 요약
[INTRODUCTION] Proton pump inhibitor (PPI) use has been associated with reduced immune checkpoint inhibitor (ICI) efficacy in metastatic non-small cell lung cancer (mNSCLC) with evidence limited to their use during a short time period around ICI initiation. This study evaluated the associations between the timing and intensity of PPI exposure up to one year before ICI initiation and overall survival (OS) in mNSCLC patients treated with ICIs.
[METHODS] This retrospective cohort study included consecutive mNSCLC patients treated with ICIs within routine clinical practice. Patients were grouped by the timing of PPI exposure from 365 days before to 30 days after (-365 to +30 days) ICI initiation: (1) no PPIs within -365 to +30 days; (2) PPIs only within -365 to -31 days; and (3) PPIs also within ±30 days of ICI initiation. The intensity of PPI exposure was quantified with the total defined daily doses (DDDs). OS was estimated using Kaplan-Meier methods, and associations between PPI exposure and OS were analyzed using Cox proportional hazards models.
[RESULTS] Of 391 patients included (median age 64.7 years, 58.6% male), 73.4% had access to PPI within -365 to +30 days of ICI initiation. PPI exposure within ±30 days (220 patients) was associated with reduced median OS (mOS) compared with no PPI exposure between -365 and +30 days of ICI initiation (mOS 15.4 vs 21.9 months; adjusted hazard ratio [aHR] 1.373, 95% CI 1.007-1.873, p = 0.045). High-intensity PPI exposure within -365 to +30 days of ICI initiation (DDD > 159; 108 patients) was also associated with reduced mOS compared with no PPI exposure in this period (mOS 13.4 vs 21.9 months; aHR 1.454, 95% CI 1.023-2.067, p = 0.037).
[DISCUSSION] PPI use around ICI initiation as well as PPI treatment intensity over a wider period was associated with reduced OS. Efforts should be made to streamline PPI use.
[METHODS] This retrospective cohort study included consecutive mNSCLC patients treated with ICIs within routine clinical practice. Patients were grouped by the timing of PPI exposure from 365 days before to 30 days after (-365 to +30 days) ICI initiation: (1) no PPIs within -365 to +30 days; (2) PPIs only within -365 to -31 days; and (3) PPIs also within ±30 days of ICI initiation. The intensity of PPI exposure was quantified with the total defined daily doses (DDDs). OS was estimated using Kaplan-Meier methods, and associations between PPI exposure and OS were analyzed using Cox proportional hazards models.
[RESULTS] Of 391 patients included (median age 64.7 years, 58.6% male), 73.4% had access to PPI within -365 to +30 days of ICI initiation. PPI exposure within ±30 days (220 patients) was associated with reduced median OS (mOS) compared with no PPI exposure between -365 and +30 days of ICI initiation (mOS 15.4 vs 21.9 months; adjusted hazard ratio [aHR] 1.373, 95% CI 1.007-1.873, p = 0.045). High-intensity PPI exposure within -365 to +30 days of ICI initiation (DDD > 159; 108 patients) was also associated with reduced mOS compared with no PPI exposure in this period (mOS 13.4 vs 21.9 months; aHR 1.454, 95% CI 1.023-2.067, p = 0.037).
[DISCUSSION] PPI use around ICI initiation as well as PPI treatment intensity over a wider period was associated with reduced OS. Efforts should be made to streamline PPI use.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
- Humans
- Proton Pump Inhibitors
- Immune Checkpoint Inhibitors
- Male
- Female
- Carcinoma
- Non-Small-Cell Lung
- Retrospective Studies
- Lung Neoplasms
- Aged
- Middle Aged
- Time Factors
- 80 and over
- Treatment Outcome
- Neoplasm Metastasis
- carcinoma
- gastrointestinal microbiome
- immune checkpoint inhibitors
- non-small-cell lung
- proton pump inhibitors
- survival analysis
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.
- Early local immune activation following intra-operative radiotherapy in human breast tissue.